Neurogene Inc. (NGNE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$124.5M
Cash & Equivalents
$26.1M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$790M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05898620 | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | PHASE3 | Active Not Recruiting | 33 |
| NCT05228145 | Gene Therapy Study for Children With CLN5 Batten Disease | PHASE2 | Active Not Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.